Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Inventory (2016 - 2025)

Amicus Therapeutics filings provide 10 years of Inventory readings, the most recent being $228.8 million for Q4 2025.

  • On a quarterly basis, Inventory rose 92.64% to $228.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $228.8 million, a 92.64% increase, with the full-year FY2025 number at $228.8 million, up 92.64% from a year prior.
  • Inventory hit $228.8 million in Q4 2025 for Amicus Therapeutics, up from $177.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $228.8 million in Q4 2025 to a low of $13.3 million in Q3 2022.
  • Median Inventory over the past 5 years was $54.2 million (2023), compared with a mean of $72.0 million.
  • Biggest five-year swings in Inventory: tumbled 39.87% in 2022 and later surged 328.99% in 2023.
  • Amicus Therapeutics' Inventory stood at $26.8 million in 2021, then decreased by 11.19% to $23.8 million in 2022, then soared by 150.66% to $59.7 million in 2023, then skyrocketed by 98.98% to $118.8 million in 2024, then soared by 92.64% to $228.8 million in 2025.
  • The last three reported values for Inventory were $228.8 million (Q4 2025), $177.9 million (Q3 2025), and $154.9 million (Q2 2025) per Business Quant data.